Revolution Medicines’ oral RAS(ON) inhibitor daraxonrasib (Rasonque) received FDA approval for metastatic pancreatic ductal adenocarcinoma after prior systemic therapy or for patients not eligible for multiagent systemic treatment. Despite the milestone, Revolution’s stock largely failed to sustain an immediate surge, signaling investor debate over valuation and near-term expectations. In RASolute 302 (NCT06625320), the drug reportedly delivered a median overall survival of 13.2 months versus 6.7 months with investigator’s choice chemotherapy in the intent-to-treat population. The approval also followed Breakthrough Therapy and Orphan Drug designations, and a priority review facilitated by the Commissioner’s National Priority Voucher program. The market reaction described alongside the approval suggests stakeholders are weighing clinical impact against pricing and commercial ramp risk, even as the regulator’s decision provides a clear clinical validation event for an oral RAS-targeted approach in a historically difficult setting.